Auro Laboratories Ltd

Dematerialisation processing status

• Dematerialisation requests processed and confirmed to depositories.
• Securities dematerialised have been listed on the stock exchanges.
• Physical certificates were mutilated and cancelled after verification; depository's name substituted as registered owner within timelines.
• Details of dematerialised certificates provided for the period.

Auro Laboratories Limited – Trading Window closed from October 01, 2026 for the quarter and half-year ended September 30, 2026; The Trading Window shall open 48 hours after the Un-audited Financial Results for the Quarter and half year ended September 30, 2026, becomes generally available.

Financials

• Revenue from operations: 876.81 Lakhs; Total income: 887.64 Lakhs.
• Expenses: 774.59 Lakhs; PBT before exceptional items: 113.05 Lakhs.
• Profit after tax: 104.56 Lakhs; EPS basic/diluted: 1.68 Rs.
• Quarter ended 30-Jun-2026, unaudited standalone results.

Notes

• Single segment: Pharmaceuticals.
• Unaudited standalone results prepared per Ind AS 34; limited review.

AGM Details

• Date and time: August 11, 2026 at 11:30 IST; Mode: VC/OAVM.
• Record date for voting: August 4, 2026.

Resolutions put to vote

• Item 1 (Ordinary): Adopt audited financial statements for year ended March 31, 2026.
• Item 2 (Ordinary): Reappointment of Kiran Kulkarni by rotation.
• Item 3 (Ordinary): Ratify remuneration to Cost Auditors for FY 2026-27.
• Item 4 (Special): Re-appointment of Whole-Time Director for 3 years.

Voting results

• Item 1: Passed with requisite majority; 1 vote against.
• Item 2: Passed with requisite majority; no votes against.
• Item 3: Passed with requisite majority; no votes against.
• Item 4: Passed with requisite majority; no votes against.

Dividend

• Dividend: No dividend proposed or declared.

Director changes

• Director changes: Kiran Kulkarni reappointed by rotation.
• Director changes: Kiran Suresh Kulkarni reappointed as Whole-Time Director for three years.

Auditors

• Cost Auditor remuneration: Ratified for FY 2026-27.

Material related party transactions

• RPTs: None disclosed at AGM.

Other material approvals

• Other approvals: None disclosed.

AGM details

• AGM held Aug 11, 2026 at 11:30 a.m. via VC/OAVM; concluded 12:05 p.m.

Key resolutions

• Ordinary resolution to receive, consider and adopt Audited Financial Statements for the year ended March 31, 2026.
• Ordinary resolution to re-appoint Mr. Kiran Kulkarni who retires by rotation.
• Special resolution to ratify remuneration payable to Poddar & Co., Cost Auditors for 2026-2027.
• Special resolution to re-appoint Mr. Kiran Suresh Kulkarni as Whole-Time Director for 3 years.

Voting status

• Voting results pending disclosure; to be shared on the company website and BSE within two working days.

Directors

• Rotation-based re-appointment of Kiran Kulkarni (DIN 09175595).
• Re-appointment of Kiran Suresh Kulkarni as Whole-Time Director for 3 years.

Auditors

• Remuneration ratification for Cost Auditors for 2026-2027.

Related party transactions

• No material related party transactions disclosed in this AGM.

Meeting Details

• Board meeting scheduled for August 14, 2026; time and venue not disclosed.

Key Agenda Items

• Unaudited financial results for quarter ended June 30, 2026 to be considered and approved with Limited Review Report.
• Any other matter with the permission of the Chair.

Other Notes

• Trading window to remain closed until 45 hours after the conclusion of the meeting for all Designated Persons and their immediate relatives.

AGM notice and annual report access

• 37th AGM scheduled Aug 11, 2026 at 11:30 AM via VC/OAVM.
• Annual Report for FY2025-26 available on company website with direct path.
• Cut-off date for email registration is July 10, 2026.
• KYC updates and dematerialization of physical securities emphasized for holders.
• Website path for annual report: aurolabs.com/contact/index.htm.

Financial performance

• Revenue from operations: 3,073.98 L, up from 1,912.39 L.
• Total income: 3,274.91 L, up from 2,005.44 L.
• Net profit after tax: 353.29 L; EPS: 5.67.
• Profit before tax: 480.82 L; depreciation: 281.02 L; finance cost: 425.29 L.
• Total comprehensive income: 337.95 L; OCI: (15.34) L.
• Dividend for 2025-26: not proposed.

Capital structure & liquidity

• Authorized share capital: 7 crore; paid-up capital: 623.25 L; total equity: 4,634.76 L.
• Borrowings total: 6,330.52 L; non-current 4,331.35 L; current 1,999.17 L.
• Cash & cash equivalents: 136.69 L; bank balances: 30.04 L.
• Dematerialised shareholding: 88.96%; promoters hold 52.18% collectively.
• Current ratio 1.08; debt-equity 1.37; ROE 7.91%; Debt Service Coverage 2.21.

Operations & capacity expansion

• Metformin HCL capacity expanded to 3600 MTA; other product expansions.
• Single-segment Bulk Drugs business; manufacturing of APIs.

Governance & board

• Kavita Sharma reappointed Independent Director for 2026–31 (Feb 11, 2026).
• Board size 6; 3 independent including one woman.
• CFO appointed May 30, 2025; CFO resigned May 30, 2026.
• Company Secretary: Priyanka Gupta resigned Sept 30, 2025; Padma Tapariya appointed Oct 1, 2025.
• Independent Directors’ meeting held Feb 5, 2026.

Auditors & compliance

• Statutory auditors: B. L. Dasharda & Associates; Cost auditors: Poddar & Co; Secretarial: GMJ & Associates.
• No material qualifications in auditor reports; no fraud reported.
• CFO appointment delay noted; non-disqualification certificate issued.

Risks & outlook

• Outlook favorable due to metformin demand and capacity expansion.
• Opportunities: EU-GMP, WHO-GMP, CEP; CDMO potential; continuous manufacturing.
• Risks: raw material volatility; regulatory compliance; export vs domestic demand; currency risk.

CSR & HR

• CSR not applicable for the year; 78 employees as of 31 Mar 2026.
• Maternity benefits as per law; health, safety and welfare measures in place.

Shareholder information

• ISIN INE292C01011; listing on BSE; scrip code 530233.
• Dematerialised holding: 88.96%; top promoters Sharat Deorah 18.71%, Auro Impex 18.75%.
• Promoter group holding: 52.18%; total shares: 6,232,500.